Board of Directors
Guillermo Herrera, Chairman and Chief Executive Officer, Altan Pharma Ltd.
Guillermo Herrera is Chairman, Chief Executive Officer and a Founder of Altan Pharma Ltd. Herrera has more than 35 years of experience in pharmaceuticals, hospital products and other health care markets. Prior to founding Altan, Mr. Herrera was a founder, and the CEO and Chairman of Pinnacle Biologics. Herrera successfully exited Pinnacle in 2013 selling it to Concordia Healthcare Corporation of Canada. Prior to Pinnacle, Herrera was CEO of Neopharm. Earlier, Herrera enjoyed a 25 year career at Abbott Laboratories where he was a corporate officer and held numerous senior executive positions including Senior Vice President and President of Abbott International, Vice President of European Operations, Vice President of Latin America and Canada, and General Manager of Abbott Spain. Mr. Herrera earned his MBA at Northwestern University.
Stafford O’Kelly, Executive Vice President and Chief Financial Officer, Altan Pharma Ltd.
Mr. O’Kelly is Executive Vice President, Chief Financial Officer and a Founder of Altan Pharma Ltd. O’Kelly has more than 30 years of experience in global health care markets. Prior to founding Altan, O’Kelly had a 29 year career with Abbott Laboratories where he was a corporate officer and held numerous executive positions in general management and finance. His most recent position at Abbott was President of Abbott Molecular Inc. Prior to that role, O’Kelly held numerous other senior leadership positions including, Vice President of Latin America & Canada; Vice President, Finance, Abbott International; Vice President Finance, TAP Pharmaceuticals; and Division Vice President and Controller, Abbott Nutrition. Mr. O’Kelly earned his MBA and his BA BAI at Trinity College Dublin.
Mark Gorman, Executive Vice President and Chief Business Development Officer, Altan Pharma Ltd.
Mark Gorman is Executive Vice President, Chief Business Development Officer and a Founder of Altan Pharma Ltd. Gorman has more than 30 years of leadership experience in global pharmaceutical, medical device, diagnostic and nutritional markets. Prior to founding Altan, Gorman was Vice President and Group Executive, IDEX Health and Science. Prior to IDEX, Gorman had a 23 year career at Abbott Laboratories where he was a corporate officer and held numerous senior management positions including Vice President and General Manager Adult Nutrition; Vice President, Europe Region; Vice President and General Manager Abbott Japan; and, several other international general management roles. Mr. Gorman earned his MBA from the University of Arizona and a B.S. in Accounting from Marquette University. He also earned his CPA certificate from the State of Illinois.
Holger Liepmann, Executive Vice President and Chief Operating Officer, Altan Pharma Ltd.
Holger Liepmann is Chief Operating Officer and a Founder of Altan Pharma Ltd. Liepmann has more than 35 years of senior leadership experience in health care markets. Prior to founding Altan, Mr. Liepmann was a corporate officer at Abbott Laboratories where he held numerous senior positions. In his last role at Abbott, Liepmann was Executive Vice President of Global Nutritionals. Earlier, Liepmann held numerous senior management positions including Executive Vice President of Global Pharmaceuticals; Senior Vice President and President, Abbott International; Vice President and General Manager Abbott Japan; Vice President, Europe Region; General Manager, Abbott Spain; and several other international management roles. Mr. Liepmann holds an MBA from Stanford and a BA from Dartmouth.
Adrian Howd, Ph.D, Non-Executive Director, Altan
Dr. Adrian Howd currently serves as chief executive officer of Malin Plc. Prior to Malin, Dr. Howd held both sell-side and buy-side roles, being a highly ranked sell-side analyst at Berenberg, Nomura and ABN Amro where he was Global Head of Healthcare Research. He also gained buy-side experience running a healthcare portfolio as part of the Principal Strategies Group at ABN Amro. Dr. Howd also served as Executive Vice President, Head of Neuroscience and Corporate Development at Evotec AG. Dr. Howd has a Ph.D in molecular neuroscience from the University of London. Dr. Howd is a principal, director and shareholder of Brandon Point Industries and is also a director of Malin Plc.
Sean Murphy, Non-executive Director
Sean Murphy is a Senior Advisor at Evercore Partners, a leading investment banking advisory firm. Prior to Evercore, Murphy was the Head of Corporate M&A and Business Development at Abbott Laboratories. In a career that spans over thirty years, Mr. Murphy’s experience in the life sciences sector is both operational and transactional, having run Abbott’s vascular business and played a leading role in a number of strategic investments during his tenure. Mr. Murphy is a director of Malin Plc and a director and shareholder of Brandon Point Industries.